

Singapore Association of Pharmaceutical Industries (SAPI) announces new leaderships

August 31, 2022 | News | By Hithaishi C Bhaskar

Ms Poh Hwee Tee (Country President, Novartis) will serve as President, while Mr Vinod Narayanan (Country President, AstraZeneca) and Ms Erika Pagani (Country Manager, Pfizer) will take over as the two Vice Presidents of SAPI



The Singapore Association of Pharmaceutical Industries (SAPI) announced that Ms Poh Hwee Tee (Country President, Singapore and Asia Emerging Markets, Novartis) will be the new President of the association, effective immediately. She replaces outgoing President, Mr Guillermo Frydman (Johnson & Johnson), who played a leading role in the association for the past two years.

In addition, Mr Vinod Narayanan (Country President, AstraZeneca) and Ms Erika Pagani (Country Manager, Pfizer) will take over as the two Vice Presidents of SAPI.

As President of SAPI, Ms Poh will represent SAPI on all matters pertaining to the association with a focus on fostering greater collaborations with policy makers, healthcare providers, patient groups and all other relevant stakeholders to improve access to innovative medicines and vaccines.

Established in 1966, SAPI currently comprises 41 members, including 33 global biopharmaceutical companies in Singapore, employing close to 10,000 people in the country. Manufacturing output of pharmaceutical and biological products in 2021 amounted to \$17.5 billion, accounting for close to 5 percent of Singapore's manufacturing activity.

Expressing the welcome note, SAPI's Executive Director Christina Teo said "Hwee Tee will continue to strengthen SAPI's strategic advocacy efforts with key stakeholders and enhance access to innovative medicines and vaccines in Singapore as we work towards advancing Singapore's position as a global biopharmaceutical hub and supporting the country in achieving its Healthier SG objectives."

Ms Poh previously held the position of Vice-President of the association in 2021 and served as the Chair of SAPI's Research & Development Committee since July 2020.

Mr Narayanan comes with two decades of experience across the U.S. notably being involved in successful negotiations for cancer treatment access in Malaysia and Singapore.

Ms Pagani has been working across the business and deep expertise in the vaccine portfolio while holding multiple leadership roles in Pfizer U.S. and Latin America. She has served on the board of SAPI since January 2021 and was appointed Chair of SAPI's Public Policy Committee in April 2022.